Linda A. deGraffenried

Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity

Linda A. deGraffenried, William E. Friedrichs, Douglas Russell et al. · Clinical Cancer Research · 2004 · 384 citations

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

Viktor Grünwald, Linda A. deGraffenried, Douglas Russel et al. · PubMed · 2002 · 272 citations

Molecular Pharmacology, Urology, Chemoprevention Strategy +14

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

Josep Maria Peralba, Linda A. deGraffenried, William E. Friedrichs et al. · PubMed · 2003 · 179 citations

Mtor-interacting Agents, Pharmacodynamic Evaluation, Pharmacotherapy +17

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

Linda A. deGraffenried, Letitia C. Fulcher, William E. Friedrichs et al. · Annals of Oncology · 2004 · 174 citations · Full text

Breast Oncology, Signaling Pathway, Cell Regulation +10

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

M. Beeram, Qing Tan, RR Tekmal et al. · Annals of Oncology · 2007 · 170 citations